Suppr超能文献

丁型肝炎感染:从最初发现到当前的研究性治疗

Hepatitis D infection: from initial discovery to current investigational therapies.

作者信息

Da Ben L, Heller Theo, Koh Christopher

机构信息

Digestive Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

出版信息

Gastroenterol Rep (Oxf). 2019 Jun 23;7(4):231-245. doi: 10.1093/gastro/goz023. eCollection 2019 Aug.

Abstract

Hepatitis D is the most severe form of viral hepatitis associated with a more rapid progression to cirrhosis and an increased risk of hepatocellular carcinoma and mortality compared with hepatitis B mono-infection. Although once thought of as a disappearing disease, hepatitis D is now becoming recognized as a serious worldwide issue due to improvement in diagnostic testing and immigration from endemic countries. Despite these concerns, there is currently only one accepted medical therapy (pegylated-interferon-α) for the treatment of hepatitis D with less than desirable efficacy and significant side effects. Due to these reasons, many patients never undergo treatment. However, increasing knowledge about the virus and its life cycle has led to the clinical development of multiple promising new therapies that hope to alter the natural history of this disease and improve patient outcome. In this article, we will review the literature from discovery to the current investigational therapies.

摘要

丁型肝炎是病毒性肝炎最严重的一种形式,与乙型肝炎单一感染相比,它向肝硬化进展更快,肝细胞癌风险增加,死亡率也更高。尽管丁型肝炎曾一度被认为是一种正在消失的疾病,但由于诊断检测的改进以及来自流行国家的移民,现在它已被公认为一个严重的全球性问题。尽管存在这些担忧,但目前治疗丁型肝炎只有一种被认可的药物疗法(聚乙二醇化干扰素-α),其疗效不尽人意且有显著副作用。由于这些原因,许多患者从未接受治疗。然而,对该病毒及其生命周期的了解不断增加,已促使多种有前景的新疗法进入临床开发阶段,有望改变这种疾病的自然病程并改善患者预后。在本文中,我们将回顾从发现该病毒到当前研究性疗法的相关文献。

相似文献

1
Hepatitis D infection: from initial discovery to current investigational therapies.
Gastroenterol Rep (Oxf). 2019 Jun 23;7(4):231-245. doi: 10.1093/gastro/goz023. eCollection 2019 Aug.
2
Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options.
Antiviral Res. 2015 Oct;122:112-29. doi: 10.1016/j.antiviral.2015.08.009. Epub 2015 Aug 11.
3
Chronic hepatitis delta: A state-of-the-art review and new therapies.
World J Gastroenterol. 2019 Aug 28;25(32):4580-4597. doi: 10.3748/wjg.v25.i32.4580.
5
NIH consensus development statement on management of hepatitis B.
NIH Consens State Sci Statements. 2008;25(2):1-29.
6
Hepatitis delta infection - Current and new treatment options.
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):321-327. doi: 10.1016/j.bpg.2017.05.001. Epub 2017 May 22.
7
Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.
Drugs. 2006;66(14):1831-51. doi: 10.2165/00003495-200666140-00005.
8
Antiviral therapy for chronic hepatitis B: a review.
Curr Drug Targets Inflamm Allergy. 2004 Mar;3(1):63-70. doi: 10.2174/1568010043483908.
9
Coinfection of Schistosoma Species with Hepatitis B or Hepatitis C Viruses.
Adv Parasitol. 2016;91:111-231. doi: 10.1016/bs.apar.2015.12.003. Epub 2016 Feb 5.
10
Management of viral hepatitis B.
J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S125-45. doi: 10.1046/j.1440-1746.17.s1.3.x.

引用本文的文献

2
A call to reclassify the delta hepatitis virus as an orphan disease.
Hepatol Commun. 2025 Jun 9;9(7). doi: 10.1097/HC9.0000000000000746. eCollection 2025 Jul 1.
3
Current and future therapeutic options for chronic hepatitis D virus infection.
Front Cell Infect Microbiol. 2025 Feb 11;14:1382017. doi: 10.3389/fcimb.2024.1382017. eCollection 2024.
4
Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients.
Biomedicines. 2025 Jan 23;13(2):280. doi: 10.3390/biomedicines13020280.
7
Assessment of performance and comparison of three commercial HDV RNA detection assays: implications for diagnosis and treatment monitoring.
Front Cell Infect Microbiol. 2024 Jun 26;14:1422299. doi: 10.3389/fcimb.2024.1422299. eCollection 2024.
8
Autoimmune Hepatitis Induced by Hepatitis Delta Virus: A Conundrum.
GE Port J Gastroenterol. 2023 Aug 16;31(3):203-208. doi: 10.1159/000531773. eCollection 2024 Jun.
9
Understanding the Natural History of Chronic Hepatitis D: Proposal of a Model for Cost-Effectiveness Studies.
Pharmacoecon Open. 2024 Mar;8(2):333-343. doi: 10.1007/s41669-023-00466-3. Epub 2024 Jan 3.
10
Performance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis.
J Clin Transl Hepatol. 2023 Nov 28;11(6):1368-1376. doi: 10.14218/JCTH.2022.00107. Epub 2023 Jun 14.

本文引用的文献

1
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27.
2
Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.
Clin Infect Dis. 2019 Aug 1;69(4):709-712. doi: 10.1093/cid/ciz001.
3
Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis.
Gut. 2019 Mar;68(3):512-521. doi: 10.1136/gutjnl-2018-316601. Epub 2018 Sep 18.
4
Current and Future Management of Chronic Hepatitis D.
Gastroenterol Hepatol (N Y). 2018 Jun;14(6):342-351.
5
Epidemiology and clinical outcomes of hepatitis delta (D) virus infection in Queensland, Australia.
Int J Infect Dis. 2018 Sep;74:123-127. doi: 10.1016/j.ijid.2018.07.005. Epub 2018 Jul 9.
6
Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
J Viral Hepat. 2018 Nov;25(11):1384-1394. doi: 10.1111/jvh.12947. Epub 2018 Jul 10.
7
Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections.
Curr Opin Virol. 2018 Jun;30:68-79. doi: 10.1016/j.coviro.2018.04.004. Epub 2018 May 15.
10
Emerging Therapeutic Targets for Hepatitis Delta Virus Infection.
Gastroenterol Hepatol (N Y). 2018 Jan;14(1):47-49.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验